venBio Global Strategic Fund II L.P. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-09-15 5:00 pm Sale | 2022-09-13 | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 714,000 1.900% | -1,601,893 (-69.17%) | Filing |
| 2021-05-07 4:13 pm Sale | 2021-05-04 | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 2,315,893 6.650% | -352,824 (-13.22%) | Filing |
| 2020-09-09 5:26 pm Sale | 2020-09-04 | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 2,668,717 7.700% | -653,421 (-19.67%) | Filing |